Actavis launches Gemcitabine on patent expiry in EU markets

The international generic pharmaceuticals company, Actavis Group, has launched the oncology product Gemcitabine in EU markets, at patent expiry. This launch represents a significant milestone in Actavis’ developing hospital business. The pharmacuetical drug Gemcitabine is the first major oncology product to be made available by Actavis on the date of patent ... Read More...